Navigation Links
What is the most effective therapy for low-dose aspirin induced peptic ulcer?
Date:2/19/2009

The incidence of low-dose aspirin-induced peptic ulcer seems to be increasing in Japan in conjunction with the increasing proportion of elderly individuals, in whom metabolic syndrome frequently develops. However, a therapeutic and prevention strategy for such peptic ulcers has not yet been established.

A research team led by Dr. Satoshi Mochida from Japan addressed this question. Their study will be published on February 14, 2009 in the World Journal of Gastroenterology.

In their study, Upper gastrointestinal endoscopy was performed in 68 patients receiving daily low-dose aspirin (81 or 100 mg/day). The endoscopic findings were classified according to the Lanza score, and the scores were compared between groups categorized according to the concomitant use of anti-ulcer drugs and the types of drugs used. In another study, 31 hemorrhagic peptic ulcer patients who had been receiving low-dose aspirin were enrolled. The patients were randomly classified into the proton pump inhibitor (PPI)-treated group and the H2 receptor antagonist (H2RA)-treated group. The administration of low-dose aspirin was continued concomitantly, and endoscopic examinations were performed 8 wk later.

They found that the Lanza scores (mean SD) of the gastro-mucosal lesions were 1.0 1.9 and 1.9 2.3 in 8 and 16 patients receiving prevention therapy with a PPI and an H2RA, respectively. Both scores were significantly smaller than the scores in 34 patients who were not receiving prevention therapy (4.7 1.0) and in 10 patients receiving cytoprotective anti-ulcer drugs (4.3 1.6). In the prospective study, 18 and 13 patients received a PPI and an H2RA, respectively. Endoscopic examinations revealed that the tissue in the region of the gastro-mucosal lesions had reverted to normal in all patients in the PPI-treated group and in 12 patients (92%) in the H2RA-treated group; no significant differences were observed between the groups.

Their results indicated that H2RA therapy was effective for both the prevention and treatment of low-dose aspirin induced peptic ulcers, similar to the effects of PPIs, while cytoprotective anti-ulcer drugs were ineffective in preventing peptic ulcers.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Related medicine news :

1. Study shows ultrasound and tPA effective for stroke
2. National Pharmaceutical Council on Economic Stimulus Package: Comparative Effectiveness Research Funding Should Target Improvements in Quality of Patient Care
3. MU researcher demonstrates non-traditional therapy is effective as pain management
4. Absolutely PR's Maggie Holben Participates In CBSA BioBreakfast Expert Panel "How to Garner Media Attention & Effectively Use Public Relations Tactics"
5. Newly Published Menopause Study: Bioidentical and FDA-Approved Divigel(R) (estradiol gel) 0.1 Percent Safe and Effective Treatment for Moderate to Severe Hot Flashes Associated With Menopause
6. Drug Rehab Mountainside Treatment Center is an Effective and Quality Option for Those Seeking Drug Treatment - Located Close to NY MA
7. Union Springs Pharmaceuticals Introduces New, More Effective Respirator
8. Early switch from IV to oral meds is effective for children with acute bone infection
9. Patients Will Benefit From Comparative Effectiveness Funding in Stimulus Bill
10. During National Wise Health Consumer Month: Consumers Seek Cost-Effective Health Care
11. Study questions effectiveness of $80 million per year brain exercise products industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... century approach to infusing high speed technology into the fabric of an entire ... the advancement of healthcare and wellness in a yet-to-be-named, health focused campus. Leading ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere ... Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is ... of providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... joined the Peoples Health network on Dec. 1, 2016. Peoples Health, a Metairie-based ... Medical Center is an exciting addition to our provider network, and the addition ...
(Date:1/17/2017)... ... 2017 , ... A prescription medication bottle, pocket knife, luggage and a solar-powered ... Product Design Challenge , the Cradle to Cradle Products Innovation Institute has ... scheduled to run through early 2018. The challenges are presented by the Institute in ...
(Date:1/17/2017)... Livingston, NJ (PRWEB) , ... January 17, 2017 , ... ... services and financial planning assistance to communities throughout the region, is launching a charity ... , Heart disease is by far the deadliest killer in America, and is responsible ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... BALTIMORE , Jan. 17, 2017 Paragon ... to provide product development services for a variety ... Diseases (NIAID) medical product development activities. The ... a contractor pool for task order awards up ... global leader in manufacturing and process development of ...
(Date:1/17/2017)... Management to Discuss Acquisition of Oncology ... On Track For An NDA Submission to ...   ... KTOV ; TASE: KTOV), an innovative biopharmaceutical company, announced that it will ... Eastern Time to discuss the recent acquisition of a majority stake in TyrNovo, ...
(Date:1/17/2017)... Jan. 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: ... been enrolled in a Phase 3 clinical trial comparing ... care (BSC) in the prevention of hepatic veno-occlusive disease ... cell transplant (HSCT) who are at high risk or ... clinical trial will be conducted across approximately 100 medical ...
Breaking Medicine Technology: